Probenecid ameliorates testosterone‐induced benign prostatic hyperplasia: Implications of PGE‐2 on ADAM‐17/EGFR/ERK1/2 signaling cascade
Journal of Biochemical and Molecular Toxicology · 2023
DOI: 10.1002/jbt.23450 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2023. Verfasst von Maha M Abdel-Fattah und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt. Hauptthemen laut MEDLINE: Testosterone, Prostatic Hyperplasia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 87 Literaturangaben.
Abstract (Originalsprache)
Benign prostatic hyperplasia (BPH) is one of the most prevalent clinical disorders in the elderly. Probenecid (Prob) is a well‐known FDA‐approved therapy for gout owing to its uricosuric effect. The present study evaluated the use of Prob for BPH as a COX‐2 inhibitor. Prob (100 and 200 mg/kg) was intraperitoneally injected into male Wistar rats daily for 3 weeks. In the second week, testosterone (3 mg/kg) was subcutaneously injected to induce BPH. Compared with BPH‐induced rats, Prob treatment reduced prostate weight and index and improved histopathological architecture. The protease activity of ADAM‐17/TACE and its ligands (TGF‐α and TNF‐α) were regulated by prob, which in turn abolished EGFR phosphorylation, and several inflammatory mediators (COX‐2, PGE2, NF‐κB (p65), and IL‐6) were suppressed. By reducing the nuclear import of extracellular regulated kinase protein 1/2 (ERK1/2), Prob helped re‐establish the usual equilibrium between antiapoptotic proteins like Bcl‐2 and cyclin D1 and proapoptotic proteins like Bax. All of these data point to Prob as a promising treatment for BPH because of its ability to inhibit COX‐2‐syntheiszed PGE2 and control the ADAM‐17/TGF‐α‐induced EGFR/ERK1/2 signaling cascade. These findings might help to repurpose Prob for the treatment of BPH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian-Russian University, Cairo, Egypt.
Zitieren
APA
Abdel-Fattah, M. M., Abo-El Fetoh, M. E., Afify, H., Ramadan, L. A. A., & Mohamed, W. R. (2023). Probenecid ameliorates testosterone‐induced benign prostatic hyperplasia: Implications of PGE‐2 on ADAM‐17/EGFR/ERK1/2 signaling cascade. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.23450
Vancouver
Abdel-Fattah MM, Abo-El Fetoh ME, Afify H, Ramadan LAA, Mohamed WR. Probenecid ameliorates testosterone‐induced benign prostatic hyperplasia: Implications of PGE‐2 on ADAM‐17/EGFR/ERK1/2 signaling cascade. Journal of Biochemical and Molecular Toxicology. 2023. doi:10.1002/jbt.23450
BibTeX
@article{AbdelFattah2023,
author = {Abdel-Fattah, Maha M and Abo-El Fetoh, Mohammed E and Afify, Hassan and Ramadan, Laila A A and Mohamed, Wafaa R},
title = {Probenecid ameliorates testosterone‐induced benign prostatic hyperplasia: Implications of PGE‐2 on ADAM‐17/EGFR/ERK1/2 signaling cascade},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2023},
doi = {10.1002/jbt.23450}
}
EUVIMED